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Summary

Background
The mcr-1 gene confers transferable colistin resistance. mcr-1-positive Enterobacteriaceae (MCRPE) have attracted substantial medical, media, and political attention; however, so far studies have not addressed their clinical impact. Herein, we report the prevalence of MCRPE in human infections and carriage, clinical associations of mcr-1-positive Escherichia coli (MCRPEC) infection, and risk factors for MCRPEC carriage.
Methods
We undertook this study at two hospitals in Zhejiang and Guangdong, China. We did a retrospective cross-sectional assessment of prevalence of MCRPE infection from isolates of Gram-negative bacteria collected at the hospitals from 2007 to 2015 (prevalence study). We did a retrospective case-control study of risk factors for infection and mortality after infection, using all MCRPEC from infection isolates and a random sample of mcr-1-negative E coli infections from the retrospective collection between 2012 and 2015 (infection study). We also did a prospective case-control study to assess risk factors for carriage of MCRPEC in rectal swabs from inpatients with MCRPEC and mcr-1 negative at the hospitals and collected between May and December, 2015, compared with mcr-1-negative isolates from rectal swabs of inpatients (colonisation study). Strains were analysed for antibiotic resistance, plasmid typing, and transfer analysis, and strain relatedness.
Findings
We identified β1 6β1 non-duplicate isolates of Enterobacteriaceae, Acinetobacter spp, and Pseudomonas aeruginosa from 18 698 inpatients and β9βγ healthy volunteers. Of 17 498 isolates associated with infection, mcr-1 was detected in 76 (1%) of 5332 E coliisolates, 13 [30%], adjusted p=0·017), before hospital admission. For the colonisation study, we screened 2923 rectal swabs from healthy volunteers, of which 19 were MCRPEC, and 1200 rectal swabs from patients, of which 35 were MCRPEC. Antibiotic use before hospital admission (p<0·0001) was associated with MCRPEC carriage in 35 patients compared with 378 patients with mcr-1-negative E coli colonisation, whereas living next to a farm was associated with mcr-1-negative E coli colonisation (p=0·03, univariate
Introduction
The relentless increase in multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gramnegative bacteria is worrying and has led to several global initiatives to unify national and international agenda to combat MDR and XDR infections. 1, 2, 3, 4 Global awareness was precipitated by the rapid dissemination of carbapenem resistance mechanisms such as NDM-1, KPC, and OXA-48/181, and the realisation of the small number of antibiotics left to treat serious infections, such as colistin. 5, 6, 7, 8 Until recently, colistin resistance was reported to be mediated by chromosomal mutations and possibly imposed a fitness cost to the organism. 9, 10 Resistance to colistin is common in Klebsiella pneumoniae
and Pseudomonas aeruginosa, but rare in Escherichia coli, and because of the complex mechanism involving lipopolysaccharide structures, the thought that this mechanism might become transferable was readily dismissed.
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However, we reported the gene encoding the first transferable colistin resistance mechanism, termed mcr-1, in Enterobacteriaceae of both food-producing animal and human origins. 12 Colistin has not yet been approved for use in human beings in China, but it has been used in animals as a therapeutic drug and feed additive since the early 1980s. Thus, we speculated that the emergence and spread of mcr-1 probably occurred first in animals and spread to human beings. 12 Colistin will soon be made available in China for use in human beings for the treatment of infections caused by MDR Gramnegative pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE). However, the coexistence of mcr-1 and carbapenem resistance genes, such as blaNDM-5/9 and blaKPC-2, identified in E coli from human infections and chicken meat, is of great concern, because the occurrence of the mcr-1 gene in CRE would seriously compromise treatment options not only in China but also globally. 13 mcr-1-positive Enterobacteriaceae (MCRPE) have been reported across southeast Asia, north Africa, Europe, and North America. Hitherto, most of the bacteria carrying mcr-1 in human infections have been retrieved from historical studies with mcr-1 identified retrospectively from whole genome sequence data. 14, 15 Furthermore, very few clinical reports have shown the effect of MCRPE on patient outcomes and these reports had very small sample sizes. 16 Although colistin is not yet used in clinical practice in China, it is commonly used as the last-line antibiotic in many countries, sometimes even for empirical treatment. 8 In view of the increased reliance on colistin in the treatment of CRE and the intercontinental dissemination of mcr-1, the effect of the emergence of MCRPE in the clinical setting needs to be urgently addressed. We ascertained the prevalence of MCRPE, and the clinical associations and outcomes of mcr-1-positive E coli (MCRPEC) infections in patients in hospital from two provinces, Zhejiang and Guangdong. We also determine the prevalence of MCRPEC colonisation of patients in hospital and healthy volunteers and examine risk factors for carriage among patients. We have applied multi-locus sequence typing (MLST) analysis comparing MCRPEC and non-MCRPEC causing infections.
Methods
Study design and materials
We undertook this epidemiological and clinical study at two geographically remote tertiary care hospitals in Zhejiang and Guangdong, China. Each hospital contains more than 3000 beds and serves mainly Hangzhou (catchment of 9 million people) and Guangzhou (catchment of 13·5 million people), the capital cities, as well as a wider catchment area for neighbouring cities in each province.
First, we did a retrospective cross-sectional study to assess the prevalence and clinical characteristics of MCRPE (prevalence study). We included non-duplicate clinical isolates of Enterobacteriaceae,
Acinetobacter spp, and Pseudomonas aeruginosa from inpatients collected between Jan 1, 2007, and April 30, 2015 (Fig 1) , as part of a study of -lactam resistance. For the prevalence study, we included patients who had been admitted for 2 or more days at any units of the two hospitals and who had a sample taken more than 48 h after admission. We excluded patients with all forms of gastroenteritis and those with active bleeding from the rectum or anal fissures. The source of infection was determined as pneumonia, urinary tract infection, surgical site infection, intra-abdominal infection, line-related infection, or bacteraemia as defined by the US Centers for Disease Control and Prevention. 17 Second, we did a retrospective case-control study to assess risk factors for infection and 30-day mortality after infection with MCRPEC (infection study; Fig 1) . We included all MCRPEC identified in the prevalence study, and a sample of mcr-1-negative E coli infection (ten times the number of positive isolates) selected by a blinded random draw done by the investigators. For the random selection, we assigned a continuing number, which did not indicate any medical information, for all inpatients, followed with putting all the numbers into an electronic pool in a computer, and then selecting the numbers with a computer mouse. We included mcr-1-negative isolates collected between Jan 1, 2012, and April 30, 2015, because no mcr-1-positive isolates were collected during 2007-11.
We also did a prospective case-control study to assess risk factors for carriage of MCRPEC (colonisation study; Fig 1) . We included isolates from rectal swabs collected at the hospitals and rectal swabs from healthy volunteers attending primary care practices for routine annual physical examinations, collected from May 1, to Dec 31, 2015, assessed using clinical microbiology. For the random selection, we used the method described previously for the infection study. We compared risk factors for MCRPEC carriage (mcr-1-positive cases from inpatients) with mcr-1-negative E coli isolates from inpatients selected by a blinded random draw (12 times the number of positive isolates). For the colonisation study, we included isolates from rectal samples collected within 24 h of admission to hospital for the inpatients who were admitted for more than 2 days, and samples collected within 12 h of physical examination for the healthy volunteers. We excluded neonates, pregnant women, patients or healthy volunteers with gastroenteritis, and patients with gastrointestinal cancer, gastrointestinal surgery, peptic ulcer, gastrointestinal bleeding, inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), intestinal polyps, intestinal fistula, anal fistula, or anal fissure.
Ethical approval was given by The Second Affiliated Hospital of Zhejiang University and Sun Yat-Sen
University Zhong Shan School of Medicine. Individual consent forms were translated into Mandarin and consent was obtained for all inpatients and healthy volunteers either face to face or by phone. We excluded patients from whom we could not obtain consent (eg, patient had moved or had died). All participants held the right to withdraw from the study at any stage.
Procedures
For analysis of risk factors during infection, we procured data from electronic medical records on patient demographics, underlying medical conditions, site of infection, intensive care unit (ICU) admission, presence of immunosuppressive factors (eg, AIDS, use of corticosteroids for more than 7 days), antibiotic use within 3 months before hospital admission or in hospital before isolation of pathogen, and clinical outcomes at 30 days.
For the analysis of risk factors of colonisation study, we obtained patient demographics, ICU admission, residence, proximity to commercial animal farms, education and income, diets and drinking water, and antibiotic use before and during hospital admission from medical records and a survey questionnaire. To reduce the potential recall bias on the risk factor of proximity to commercial animal farms, we checked the location of home addresses with Google maps and Baidu maps to confirm proximity to farms.
We initially identified all isolates from the retrospective collection (Fig 1) using Columbia blood agar (Oxoid, Hampshire, UK) with 5% sheep blood (Luqiao, Beijing, China), and identified species by MALDI-TOF mass spectrometry (BrukerDaltonik GmbH, Bremen, Germany). Where the species could not be well interpreted by MALDI-TOF, we applied 16S rDNA sequencing. We screened isolates from rectal samples for the colonisation study by inoculating on Columbia blood agar. Only one suspected Enterobacteriaceae isolate was analysed per sample. To determine presence of MCRPE from rectal samples and all clinical isolates we assessed growth on media containing 2 mg/L of colistin. All isolates were subsequently screened for mcr-1 by PCR and sequencing. 12 We determined the plasmid or chromosomal location of mcr-1 gene in all MCRPEC isolates from both clinical and carriage isolates using the method previously described. 12 We investigated the frequency of transfer of mcr-1-carrying plasmid in both the infection and colonisation E coli isolates by conjugation experiments using streptomycin-resistant E coli C600 or rifampicin-resistant E coliEC600 as the recipient strains, and transfer frequencies were calculated as the number of transconjugants per recipient.
Antimicrobial susceptibility testing of all MCRPEC, as well as the mcr-1-negative E coli isolates used in the infection and colonisation studies, was done by agar dilution and interpreted according to European
Committee on Antimicrobial Susceptibility Testing clinical breakpoints (version 6.0), and the Clinical and Laboratory Standards Institute document M100-S25. 18 Whole cell DNA of all MCRPEC was prepared with the Wizard Genomic DNA Purification Kit (Promega, Beijing, China), submitted to whole genome sequencing, 18 and a draft assembly of the sequences was done with the CLC Genomics Workbench 8. 
Statistical analysis
Clinical data were collected and collated into specifically designed databases within Microsoft Excel 2013 and Minitab17 statistical software. Databases were password protected throughout the course of the study. We calculated risk factors for mcr-1-positive E coliinfection and colonisation using a two-stage approach. We used univariate statistical tests to assess key risk factors for potential association. Those significant at the 10% level were entered into multivariable logistic regression using IBM SPSS software.
Separate models were fitted for overall antibiotic use and exploration of the effect of individual classes of antibiotics. Given the categorical nature of the variables, binary data were tested by χ 2 analysis or
Fisher's exact test. Continuous data were tested with the Mann-Whitney U test.
Role of the funding source
The funder had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Prevalence of mcr-1
For the prevalence study, we analysed 17 498 isolates from 18 698 inpatients, including 10 688
Enterobacteriaceae, 3549 Acinetobacter spp, and 3261 P aeruginosa (Fig 1) . We detected mcr-1 in 76 (1%) of 5332 E coli, 13 (<1%) of 3480 K pneumoniae, one (<1%) of 890 E cloacae, and one (1%) of 162 Enterobacter aerogenes. Over the sampling period, we noted a general increase in the prevalence of mcr-1-positive E coli in both hospitals. A non-linear increase in mcr-1-positive K pneumoniae was also noted.
For the colonisation study, we analysed rectal swabs of 1200 inpatients and 2923 healthy volunteers, from which we identified 4123 Enterobacteriaceae. 35 (3%) of 1199 E coli isolates from inpatients were positive for mcr-1, and one of one E cloacae isolate from inpatients was positive; 19 (1%) of 2923 E coli isolates from healthy volunteers were positive for mcr-1.
Minimum inhibitory concentration (MIC) profiles of MCRPEC and mcr-1-negative E coli isolates
In the infection study, resistance was significantly more common in E coli isolates with mcr-1 (n=76) than in those without mcr-1(n=508) for most antimicrobial drugs tested, including not only colistin and polymyxin B, but also amoxicillin plus clavulanic acid, cefotaxime, ceftazidime, cefepime, gentamicin, amikacin, ertapenem, fosfomycin, nitrofurantoin, and ciprofloxacin (Table 1) .
There were large differences in MIC50 between MCRPEC isolates from inpatients with infections (n=76) and those from rectal swabs in healthy people (n=19), with differences of more than 32-fold for ampicillin, 512-fold for cefotaxime, 64-fold for ceftazidime, 64-fold for cefepime, and 64-fold for ciprofloxacin.
However, the MIC50 values from clinical E coli isolates from inpatients with infections (n=76) were similar to the isolates from rectal swabs from inpatients (n=35), except for ceftazidime, cefepime, and ciprofloxacin, which were eight-fold, 32-fold and 16-fold higher, respectively.
Coexistence of mcr-1 and carbapenem resistance
Among all 146 MCRPE (91 from the retrospective collection and 55 from the colonisation collection), five E coli isolates from clinical samples were carbapenem resistant: three from Zhejiang and two from 
Risk factors
For the infection study, we collected clinical data from 76 mcr-1-positive isolates and randomly selected 760 mcr-1-negative clinical E coli isolates (of which 252 were excluded because of incomplete data, leaving 508) from 4609 E coli infection cases. 30-day mortality was 7·3% for mcr-1-negative infections and 11·8% for mcr-1-positive infections. Being male, immunosuppressed, or having received antibiotics in the past 3 months were significant risk factors for mcr-1-positive infection ( Table 2 ). Use of carbapenems and fluoroquinolones in the previous 3 months was particularly associated with increased risk. Patient age was not associated with mcr-1-positivity ( Table 2) . We saw no association with either mcr-1-positive or mcr-1-negative infections in patients with neutropenia or undergoing artificial lung ventilation (Table 2 ). With only two regions (Guangdong and Zhejiang), we analysed region as a fixed effect and it was no longer significant in the multivariable model (Table 2 ).
In the colonisation study, we identified 35 MCRPEC isolates from rectal swabs of inpatients. We randomly selected 420 mcr-1-negative isolates from inpatients for comparison, of which 42 were excluded because of incomplete data, leaving 378 isolates of mcr-1-negative E coli (Fig 1; Table 3 ).
Antibiotic use before hospital admission was a major risk factor for colonisation by mcr-1-positive E coli (unadjusted p=0·0008; adjusted p<0·0001). Living in proximity to livestock was a risk factor for colonisation by mcr-1-negative E coli in the unadjusted analysis (p=0·03) but not in the adjusted analysis (p=0·995; Table 3 ).
In addition, we analysed all associations and outcomes for both mcr-1-negative E coli and MCRPEC comparing Guangdong with Zhejiang. Significant differences were noted in several social aspects between the two regions, including living place, education, income, diet, and drinking water.
High frequency of transfer of mcr-1 carrying plasmids
S1-pulsed field gel electrophoresis and Southern blotting of 130 MCRPEC (76 from the infection study and 54 [one isolate had lost the plasmid during this stage of the analysis and could not be included in these data] from the colonisation study) showed that mcr-1 was located on plasmids with sizes ranging from 32 kb to 400 kb in 123 isolates, and on the chromosome in seven isolates Among the 123 isolates carrying mcr-1 on plasmids, mcr-1 was successfully transferred to E coli EC600 or C600 on 42 (34%)
occasions. Frequency of transfer differed substantially, ranging from 10 −1 to 10
, while 29 (69%) of these 42 isolates had high conjugation rates Two main markers (Inc and Mob) of mcr-1-carrying plasmids in the transconjugants were characterised. IncX4 and IncI2 were the most prevalent Inc types identified in 13 and 14 transconjugants, respectively. Other Inc types included F (n=7), K (n=6), FIB (n=6), I1-1 (n=6), N (n=4), and FIIS (n=1). 11 transconjugants were non-typeable using the current Inc classification. Mob typing showed that P51 and F12 were found in 11 and nine transconjugants, respectively. Both H121 and Qu were found in one transconjugant, but 24 transconjugants could not be typed using the Mob system.
Diversity of MCRPEC strains
We assessed clonality and clades of both mcr-1-negative and mcr-1-positive E coli strains from the infection study (Fig 1) as minimum spanning trees for Guangdong (Fig 2A) and Zhejiang (Fig 2B) . Both the number and diversity of strains enrolled from Guangdong were greater than those from Zhejiang, The clades identified among the carriage isolates (both hospital and community) from the colonisation study were diverse from both Zhejiang and Guangdong with some commonality in the clades isolated from clinical samples-eg, ST10, ST156, ST117, and ST131 (Fig 3) . However, ST48, ST4014, and ST58
were not isolated clinically (Fig 3) .
Discussion
MCRPE gained global attention after our finding of the mobile colistin resistance mechanism MCR-1.
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Following our report of emergence of MCR-1 in both animals and human beings, we undertook a comprehensive study on the prevalence, clinical association, and carriage of MCRPE in human beings.
Analysis of the different associations and outcomes from all infections (mcr-1-negative and MCRPEC)
showed one unexpected result. There was a gender bias (p=0·011) in whether the infection was mcr- E coli ST156 belongs to phylogenetic group A and is generally not considered to be highly virulent, although a recent study from Spain would suggest otherwise. 20 ST156 has been previously reported from China and associated with MDR and XDR phenotypes, but mainly from poultry. 21 , 22 E coli ST101 is widely regarded as having environmental lineage and being associated with water and sewerage, and also poultry; however, it has been associated with carbapenem resistance and XDR clinical outbreaks. 22, 23 To the best of our knowledge, this study is the first report of E coli ST101 in mainland
China. E coli ST95 is now thought to be more pathogenic than are ST156 and ST101 and considered a human and avian pathogen. 24 E coli ST10 has only previously been reported from animals in China and thus this is the first report of ST10 from human infections in China. 25 ST131 has long been recognised as the virulent global epidemic strain associated with human disease and also displaying MDR and XDR phenotypes. 26 Until now, the only ST131 isolate reported carrying mcr-1 was from chicken meat imported into Denmark. 27 In this study, we describe three ST131 mcr-1-positive isolates from
Guangdong that would suggest colistin resistance might be associated with poorer clinical outcome than other STs. Chinese reports on patient infections suggest that E coli ST131 is prevalent 28 and thus, the probability of mcr-1plasmids further being disseminated among these pathogenic E coli seem highly likely. However, in this study, the patients infected with mcr-1-positive E coli ST131 causing skin and soft tissue, bloodstream, and urinary tract infections recovered, suggesting that in this limited sample mcr-1-positive E coli ST131 strains were not pathogenic. Some clades only found in carriage isolates-eg, ST48, ST4014, and ST58-were not isolated clinically, suggesting they could be less likely to cause disease.
We acknowledge several limitations in our study. First, although we noted significant increases of mcr- Zhejiang provinces, but cannot further speculate as to why these differences have occurred without more in-depth observations and analysis and they might not be generalisable across other provinces and all of China. Last, the risk factors that were reported by the patients and the volunteers might be confounded by recall bias.
Although there have been many reports of carbapenem resistance in Chinese hospitals, most MCRPEC were carbapenem-susceptible; however, in this study, resistance to ciprofloxacin, cefotaxime, and cefepime was especially common. These results suggest that MCRPEC were able to recruit other resistance genes and become multiply drug-resistant, which could raise difficulties in the treatment of patients with clinical infection due to MCRPEC. Despite the fact that almost all MCRPEC were colistinresistant, clinical colistin resistance in China is somewhat of an enigma because colistin is not generally used in human beings. The first report of mcr-1 in China resulted in substantial policy discussions and has encouraged the withdrawal of colistin. 29 In part, this report is likely to advocate the use of colistin in
Chinese patients and its subsequent withdrawal from the farming sector. Accordingly, this study provides a useful baseline of colistin resistance to monitor the effect of its introduction and provide predictive outcomes on treatment failures. Data are mean (SD) or n (%). *Univariate tests: everything significant at 10% level selected for multivariable models. †Model including: region, site of infection, sex, immunosuppression, abdominal or pelvic catheter, and antibiotic use in the past 3 months. ‡Model including: region, site of infection, sex, immunosuppression, abdominal or pelvic catheter, and use in the past γ months of penicillins and -lacatamase inhibitors, carbapenems, and fluoroquinolones 
